These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 22203586)
1. Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. Trancart S; Charreau I; Marchou B; Bocquentin M; Molina JM; Izopet J; Tangre P; Aboulker JP; Taburet AM; Antimicrob Agents Chemother; 2012 Mar; 56(3):1655-7. PubMed ID: 22203586 [TBL] [Abstract][Full Text] [Related]
2. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM; Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497 [TBL] [Abstract][Full Text] [Related]
3. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ; J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384 [TBL] [Abstract][Full Text] [Related]
4. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149 [TBL] [Abstract][Full Text] [Related]
5. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
6. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K; Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935 [TBL] [Abstract][Full Text] [Related]
18. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy. Rokx C; Verbon A; Rijnders BJ HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. Ford N; Shubber Z; Hill A; Vitoria M; Doherty M; Mills EJ; Gray A PLoS One; 2013; 8(11):e79981. PubMed ID: 24244586 [TBL] [Abstract][Full Text] [Related]
20. Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals. Tanaka R; Hanabusa H; Kinai E; Hasegawa N; Negishi M; Kato S Antimicrob Agents Chemother; 2008 Feb; 52(2):782-5. PubMed ID: 18070970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]